Empazin L 25 mg+5 mg (Tablet)
Unit Price: ৳ 35.00 (3 x 10: ৳ 1,050.00)
Strip Price: ৳ 350.00
Medicine Details
Category | Details |
---|---|
Generic | Empagliflozin linagliptin |
Company | Delta pharma ltd |
Also available as |
Indications
- Adjunct to diet and exercise
- Improves glycemic control
- Type 2 diabetes mellitus
Pharmacology
- Inhibits DPP-4 enzyme
- Increases concentrations of incretin hormones
- Stimulates insulin release
- Decreases glucagon levels
- Reduces hepatic glucose output
- Inhibitor of Sodium-glucose co-transporter 2 (SGLT2)
- Reduces renal reabsorption of glucose
Dosage & Administration
- Recommended dose: 10 mg Empagliflozin and 5 mg Linagliptin once daily
- Increased dose: 25 mg Empagliflozin and 5 mg Linagliptin once daily
- Assess renal function before initiating
- Do not initiate if eGFR is below 45 mL/min/1.73 m²
- Discontinue if eGFR falls below 45 ml/min/1.73 m²
Interaction
- Coadministration with diuretics
- Coadministration with Insulin or Insulin secretagogues
- Effect on P-glycoprotein or CYP3A4 Enzymes
- Positive urine glucose test
- Interference with 1,5-anhydroglucitol (1,5-AG) Assay
Contraindications
- Severe renal impairment
- End-stage renal disease or dialysis
- Hypersensitivity reaction to Linagliptin or Empagliflozin
Side Effects
- Pancreatitis
- Ketoacidosis
- Volume Depletion
- Urosepsis and Pyelonephritis
- Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues
- Necrotizing Fasciitis of the Perineum
- Genital Mycotic Infections
- Hypersensitivity Reactions
- Severe and Disabling Arthralgia
- Bullous Pemphigoid
- Heart Failure
Pregnancy & Lactation
- Not recommended during second and third trimesters of pregnancy
- Limited available data in pregnant women
- Risks associated with poorly controlled diabetes in pregnancy
Precautions & Warnings
- Pancreatitis
- Hypotension
- Acute kidney injury and impairment in renal function
- Hypoglycemia
- Genital Mycotic Infections
- Hypersensitivity
- Heart Failure
Overdose Effects
- Contact Poison Control Center
- Employ supportive measures
- Removal of unabsorbed material from the gastrointestinal tract
- Clinical monitoring
- Institute supportive treatment
Therapeutic Class
- Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Storage Conditions
- Store below 30°C
- Keep away from light and wet place
- Keep out of reach of children